GlassScriptPhysician profile
Abraham P Mathews
NPI 1568556314
$1,710.18
in general payments reported to CMS, 2019-2025
34 companies · $681 in 2025
The $681 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $81.03 · 2021: $53.03 · 2022: $97.44 · 2023: $482 · 2024: $316 · 2025: $681.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,149 · Education: $330.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,148.72 |
| Education | $329.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $197.38 | 2023-2024 | Xospata, Vyloy |
| Pfizer INC. | $187.09 | 2022-2025 | |
| Daiichi Sankyo INC. | $130.57 | 2022-2025 | Enhertu, Vanflyta |
| Abbvie INC. | $83.48 | 2025 | |
| Genzyme Corporation | $75.81 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $73.80 | 2023-2025 | Tagrisso, Imfinzi |
| Aveo Pharmaceuticals, INC. | $71.29 | 2024-2025 | |
| Histosonics, INC. | $68.96 | 2025 | |
| Genentech USA, INC. | $62.42 | 2019-2025 | Lunsumio, Columvi, Polivy |
| Regeneron Healthcare Solutions, INC. | $59.49 | 2024-2025 | Lynozyfic, Libtayo |
| Seagen INC. | $57.99 | 2023 | |
| Novartis Pharmaceuticals Corporation | $47.49 | 2019-2025 | |
| Celgene Corporation | $44.07 | 2023-2025 | Reblozyl |
| Exelixis INC. | $35.36 | 2019-2025 | Cabometyx |
| Lilly USA, LLC | $34.79 | 2023-2025 | Verzenio, Jaypirca, Retevmo |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Beone Medicines USA, INC. | $34.35 | 2025 | Tevimbra |
| Gilead Sciences, INC. | $34.10 | 2021-2024 | |
| Genmab U.S., INC. | $33.50 | 2023 | Epkinly |
| Merck Sharp & Dohme LLC | $32.82 | 2019-2023 | Keytruda |
| E.R. Squibb & Sons, L.L.C. | $31.55 | 2023-2025 | Opdualag |
| Pharmacyclics LLC, An Abbvie Company | $29.61 | 2021 | |
| Array Biopharma INC | $29.31 | 2022-2025 | Mektovi, Tukysa, Braftovi |
| Rigel Pharmaceuticals, INC. | $28.33 | 2025 | Gavreto, Tavalisse, Rezlidhia |
| Kite Pharma, INC. | $26.41 | 2023 | |
| Stemline Therapeutics INC. | $25.22 | 2023 | Orserdu |
| Ipsen Biopharmaceuticals, INC | $23.46 | 2025 | Onivyde |
| Mirati Therapeutics, INC. | $23.26 | 2023 | Krazati |
| Janssen Biotech, INC. | $22.94 | 2022 | |
| Servier Pharmaceuticals LLC | $21.73 | 2024 | |
| Alexion Pharmaceuticals, INC. | $21.19 | 2025 | Koselugo |
| Glaxosmithkline, LLC. | $18.17 | 2025 | Jemperli, Zejula |
| Incyte Corporation | $17.09 | 2023 | Pemazyre, Zynyz, Monjuvi |
| Bayer Healthcare Pharmaceuticals INC. | $15.65 | 2025 | |
| Epizyme, INC. | $11.50 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Abraham Mathews listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.